Tag: Public offering
AdaptHealth raises capital
June 30, 2020HME News Staff
PLYMOUTH MEETING, Pa. - AdaptHealth has commenced a public offering of 6.5 million shares of its Class A common stock, subject to market and other conditions. In conjunction with the offering, the company intends to grant to the underwriters a 30-day option to purchase up to 975,000 additional shares of Class A common stock. AdaptHealth plans to use the net proceeds from the offering for general corporate purposes, including acquisitions and other business opportunities, capital expenditures and...
BioScrip makes buy, announces public offering
June 14, 2016HME News Staff
DENVER - BioScrip, a provider of infusion and homecare management solutions, has entered into an agreement to buy the business of HS Infusion Holdings.
The Hammonton, N.J.-based Home Solutions provides home infusion and home nursing products and services to patients across the East Coast. Its principal shareholder is KRG Capital Partners, a Denver-based private equity firm.
“The combination of BioScrip and Home Solutions brings together two highly complementary core infusion services...
Alliqua raises $34.5M
May 5, 2015HME News Staff
LANGHORNE, Pa. - Alliqua BioMedical, a provider of advanced wound care products, has raised $34.5 million through a public offering. The company, listed on the NASDAQ as ALOA, sold about 6.6 million shares of its common stock at a price of $4.55 per share. Alliqua plans to use the net proceeds from the offering to “fund the commercial expansion of its marketed products, to opportunistically pursue additional product platforms, and for working capital and general corporate purposes,” according...
BioScrip to sell 6.8M shares in public offering
August 14, 2013HME News Staff
ELMSFORD, N.Y. - BioScrip, a provider of infusion and homecare services, has upped the ante on its public offering. The company announced Aug. 14 that it will offer 6,895,873 shares instead of 6,800,000, all of which are being sold by existing stockholders. The underwriter of the offering, Morgan Stanley, has 30 days to purchase up to an additional 1,020,000 shares from selling stockholders. BioScrip will not receive any of the proceeds from the initial sale of the shares. The offering is expected...